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potential problem in the near future regarding the management
of osteoporosis in the Asian region.
In the June issue of Osteoporosis and Sarcopenia, Ben-
jamin et at. published an article entitled “Review on the
comparison of effectiveness between bisphosphonate and
denosumab in postmenopausal women”, the results are
clear, and apparently we have a treatment option which
probably is more effective than the bisphosphonates [1]. On
the other hand, Khosla of the Mayo Clinic almost at the
same time, published an editorial on J Bone Miner Res
entitled “A crisis in the treatment of osteoporosis”, claiming
for a more positive attitude toward treating osteoporosis
patients with effective medications [2]. He quoted a stun-
ning decrease in the usage rate of bisphosphonate in
osteoporotic patients after their hip fractures, from 15% in
2004 to 3% in 2013. The main reason seems to be the
concern about the rare side effects of bisphosphonates and
other antiresorptives, namely osteonecrosis of the jaw
(ONJ), and an even less common side effect, atypical femur
fracture (AFF). We and others in Asia have surveyed the
incidence rate of ONJ after bisphosphonate treatment in the
general population and large medical centers [3]. The rate
we found in Taiwan was 0.5% per year after the first year.
Japanese colleague reported a similar rate [4]. These rates
are slightly higher than that reported in the Caucasian
population, but are in general quite low. As in the report of
Khosla, the treatment benefit should still outweigh the risk
of the side effects of bisphosphonates. Denosumab is widely
available in Asia while the rates of the side effects after its
usage have not been systematically surveyed. The anecdotal
impression was that this rates seems to be similar of less
than that of the bisphosphonates.view under responsibility of The Korean Society of Osteoporosis.
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reativecommons.org/licenses/by-nc-nd/4.0/).I would like to propose that a systematic survey of ONJ and
AFF after denosumab treatment be performed in Asian
countries, and the benefit and risk of bisphosphonate and
denosumab treatment for osteoporosis be analyzed. Then the
Asian osteoporosis societies may explain this issue clearly to
the general population. The medical personnels of course
should and will use the appropriate treatment to manage the
osteoporotic patients in their countries with more confidence.
After all we have to avoid the situation of “to fail our patients”
as mentioned in the article of Khosla.
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